NASDAQ$KURA
Kura Oncology Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Kura Oncology reported Q1 2026 with $18.3M revenue, net loss of $73.3M, and diluted loss per share of $0.83.
For the period ended 2026-03-31, Kura Oncology reported $18.3M revenue. Total revenue $18.3M incl. $5.8M product and $12.5M collaboration. R&D $65.3M. Commercial launch phase for ziftomenib with Kyowa collaboration; no numeric annual guide.
- Total revenue $18.3M incl. $5.8M product and $12.5M collaboration.
- R&D $65.3M.
- High R&D and SG&A; net loss $73.3M.
Headline financials
Revenue & EPS history
Kura Oncology · Revenue · Quarterly
$18.3M
Forward guidance
Commercial launch phase for ziftomenib with Kyowa collaboration; no numeric annual guide.
Tailwinds
- Product revenue beginning from ziftomenib.
- Strong collaboration funding.
Headwinds
- High R&D and SG&A; net loss $73.3M.
- Regulatory and launch execution risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
+0.5%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+0.9%
Avg return
30 days after
53%
21 / 40 earnings
Positive
+22.4%
Q2 2016
Best reaction
-19.3%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.7% | -2.9% | -6.8% | |
| Q4 2025 | -0.5% | +8.3% | +0.7% | |
| Q3 2025 | +2.0% | +0.9% | +22.6% | |
| Q2 2025 | -7.0% | +8.9% | +37.9% | |
| Q1 2025 | -0.6% | -13.0% | -12.3% | |
| Q4 2024 | -1.5% | -5.7% | -9.3% | |
| Q3 2024 | -0.9% | +4.1% | -40.2% | |
| Q1 2024 | +1.7% | +3.9% | +1.6% | |
| Q4 2023 | +3.1% | +4.1% | +2.8% | |
| Q3 2023 | +12.8% | +16.0% | +24.7% | |
| Q2 2023 | +7.1% | +1.3% | -2.0% | |
| Q1 2023 | +8.8% | +11.1% | +14.6% | |
| Q4 2022 | -2.2% | -0.3% | -1.4% | |
| Q3 2022 | -7.2% | -14.8% | +2.6% | |
| Q2 2022 | +1.1% | +4.2% | -0.8% | |
| Q1 2022 | -11.8% | -22.5% | -8.7% | |
| Q4 2021 | +14.6% | +13.6% | +12.9% | |
| Q3 2021 | +6.5% | +0.2% | -32.6% | |
| Q2 2021 | +0.8% | -3.4% | +8.0% | |
| Q1 2021 | +2.5% | -1.5% | -16.6% | |
| Q4 2020 | -19.3% | -10.0% | -17.8% | |
| Q3 2020 | +9.2% | +20.0% | +12.3% | |
| Q2 2020 | +15.7% | +17.0% | +36.7% | |
| Q1 2020 | +5.3% | +7.0% | +18.1% | |
| Q4 2019 | -4.3% | -3.8% | -26.1% | |
| Q3 2019 | -4.4% | +1.1% | -1.0% | |
| Q2 2019 | +0.8% | -1.2% | -20.6% | |
| Q1 2019 | +5.9% | +4.1% | +3.0% | |
| Q4 2018 | -9.0% | -1.7% | +12.3% | |
| Q3 2018 | +5.4% | +9.4% | +19.3% | |
| Q2 2018 | -13.7% | -11.2% | -7.0% | |
| Q1 2018 | -0.6% | +4.7% | +3.5% | |
| Q4 2017 | -1.3% | -13.5% | -23.8% | |
| Q3 2017 | -6.4% | +11.1% | -4.4% | |
| Q2 2017 | -13.0% | -38.2% | -32.9% | |
| Q1 2017 | +0.0% | +2.8% | -13.9% | |
| Q4 2016 | -8.5% | -6.3% | +6.9% | |
| Q3 2016 | +6.0% | +25.3% | +27.7% | |
| Q2 2016 | +22.4% | +20.1% | +43.5% | |
| Q4 2015 | +0.5% | — | — | |
| Q4 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro